Evidence map›Paper›PMID 24971791›Full record

ArticlePloS one2014

The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients.

Francesco Blasi, Giancarlo Cesana, Sara Conti, Virginio Chiodini, Stefano Aliberti, Carla Fornari, Lorenzo Giovanni Mantovani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature.The European journal of health economics : HEPAC : health economics in prevention and care · 2020
    Pooled it
  3. Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review.International journal of chronic obstructive pulmonary disease · 2020
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.International journal of chronic obstructive pulmonary disease · 2015
    Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Francesco BlasiDepartment of Pathophysiology and Transplantation, Università degli Studi di Milano, IRCCS Fondazione Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
Giancarlo CesanaCESP, Research Centre on Public Health, Department of Statistics and Quantitative Methods, University of Milano - Bicocca, Monza, Italy.
Sara ContiCESP, Research Centre on Public Health, Department of Statistics and Quantitative Methods, University of Milano - Bicocca, Monza, Italy.
Virginio ChiodiniCESP, Research Centre on Public Health, Department of Statistics and Quantitative Methods, University of Milano - Bicocca, Monza, Italy.
Stefano AlibertiDepartment of Health Sciences, University of Milano - Bicocca, Respiratory Unit, AO San Gerardo, Monza, Italy.
Carla FornariCESP, Research Centre on Public Health, Department of Statistics and Quantitative Methods, University of Milano - Bicocca, Monza, Italy.
Lorenzo Giovanni MantovaniCESP, Research Centre on Public Health, Department of Statistics and Quantitative Methods, University of Milano - Bicocca, Monza, Italy; University of Napoli Federico II, Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic Obstructive Pulmonary Disease (COPD) is a common disease with significant health and economic consequences. This study assesses the burden of COPD in the general population, and the influence of exacerbations (E-COPD) on disease progression and costs.

methodsThis is a secondary data analysis of healthcare administrative databases of the region of Lombardy, in northern Italy. The study included ≥ 40 year-old patients hospitalized for a severe E-COPD (index event) during 2006. Patients were classified in relation to the number and type of E-COPD experienced in a three-year pre-index period. Subjects were followed up until December 31st, 2009, collecting data on healthcare resource use and vital status.

results15857 patients were enrolled -9911 males, mean age: 76 years (SD 10). Over a mean follow-up time of 2.4 years (1.36), 81% of patients had at least one E-COPD with an annual rate of 3.2 exacerbations per person-year and an all-cause mortality of 47%. A history of exacerbation influenced the occurrence of new E-COPD and mortality after discharge for an E-COPD. On average, the healthcare system spent 6725€ per year per person (95%CI 6590-6863). Occurrence and type of exacerbations drove the direct healthcare cost. Less than one quarter of patients presented claims for pulmonary function tests.

conclusionsCOPD imposes a substantial burden on healthcare systems, mainly attributable to the type and occurrence of E-COPD, or in other words, to the exacerbator phenotypes. A more tailored approach to the management of COPD patients is required.

Indexed as

AgedAged, 80 and overCohort StudiesFemaleHospitalizationHumansInpatientsMalePulmonary Disease, Chronic Obstructive

Identifiers

PMID24971791
PMCPMC4074190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.